down arrow

Akero Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00973Y1082
USD
54.63
0.14 (0.26%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

54.5354.69

52 Week

21.3458.40
Valuation
Technical
Day's Volume

CASH

2.28 M

Shareholding (Mar 2025)

FII

17.61%

Held by 133 FIIs

DII

29.08%

Held by 51 DIIs

Promoter

12.57%

How big is Akero Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Akero Therapeutics, Inc. has a market capitalization of $4.42 billion, with net sales of $0.00 million and a net profit of -$269.43 million over the last four quarters. The company reported shareholder's funds of $750.11 million and total assets of $825.89 million as of Dec 24.

Market Cap: As of Jun 18, Akero Therapeutics, Inc. has a market capitalization of 4,416.35 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Akero Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -269.43 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 750.11 million and total assets of 825.89 million.

Read More

What does Akero Therapeutics, Inc. do?

22-Jun-2025

Akero Therapeutics, Inc. is a biotechnology company focused on developing treatments for non-alcoholic steatohepatitis (NASH) to restore metabolic balance. It has a market cap of approximately $4.42 billion and reported a net loss of $71 million as of March 2025.

Overview: <BR>Akero Therapeutics, Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company focused on developing medicines to restore metabolic balance and improve the health of patients with NASH, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -71 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4,416.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: -24.86% <BR>Price to Book: 4.07<BR><BR>Contact Details: <BR>Address: 601 Gateway Boulevard, Suite 350, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 650 4876488 <BR>Fax: 1 302 6555049 <BR>Website: https://www.akerotx.com/

Read More

Who are in the management team of Akero Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Akero Therapeutics, Inc. includes Mark Iwicki (Independent Non-Executive Chairman), Dr. Andrew Cheng (President and CEO), and several Independent Directors: Tomas Heyman, Kevin Bitterman, Seth Harrison, and Jane Henderson. This team is responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Akero Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Mark Iwicki, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Dr. Andrew Cheng, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Tomas Heyman, who is an Independent Director.<BR>- Mr. Kevin Bitterman, who is a Non-Executive Independent Director.<BR>- Dr. Seth Harrison, who is also a Non-Executive Independent Director.<BR>- Ms. Jane Henderson, who serves as a Non-Executive Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Akero Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 7, 2025, Akero Therapeutics, Inc. shows a mildly bullish trend overall, supported by monthly bullish indicators despite some weekly bearish signals, and has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 7 August 2025, the technical trend for Akero Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages indicate a mildly bullish stance. The Bollinger Bands show a mildly bearish signal on the weekly chart but are mildly bullish on the monthly chart. The Dow Theory indicates a mildly bearish position on both weekly and monthly time frames.<BR><BR>In terms of performance, Akero Therapeutics has outperformed the S&P 500 year-to-date with a return of 66.07% compared to the S&P 500's 12.22%, and over the past year, it has returned 71.36% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the monthly bullish indicators despite some bearish signals in the weekly metrics.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,565 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.69

stock-summary
Return on Equity

-27.68%

stock-summary
Price to Book

3.48

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-71 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.75%
0%
19.75%
6 Months
5.85%
0%
5.85%
1 Year
77.66%
0%
77.66%
2 Years
209.34%
0%
209.34%
3 Years
20.17%
0%
20.17%
4 Years
174.52%
0%
174.52%
5 Years
95.46%
0%
95.46%

Akero Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Akero Therapeutics, Inc. technically bullish or bearish?

As of 7 August 2025, the technical trend for Akero Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages indicate a mildly bullish stance. The Bollinger Bands show a mildly bearish signal on the weekly chart but are mildly bullish on the monthly chart. The Dow Theory indicates a mildly bearish position on both weekly and monthly time frames. In terms of performance, Akero Therapeutics has outperformed the S&P 500 year-to-date with a return of 66.07% compared to the S&P 500's 12.22%, and over the past year, it has returned 71.36% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the monthly bullish indicators despite some bearish signals in the weekly metrics....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-226.51%
EBIT to Interest (avg)
-82.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.99
EV to EBIT
-12.00
EV to EBITDA
-12.00
EV to Capital Employed
8.48
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-70.64%
ROE (Latest)
-24.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (40.73%)

Foreign Institutions

Held by 133 Foreign Institutions (17.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.89% vs -80.06% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-80.90",
          "val2": "-65.70",
          "chgp": "-23.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.50",
          "val2": "-56.00",
          "chgp": "-25.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -66.07% vs -35.54% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-285.40",
          "val2": "-172.80",
          "chgp": "-65.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "3.10",
          "chgp": "51.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-252.10",
          "val2": "-151.80",
          "chgp": "-66.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-80.90
-65.70
-23.14%
Interest
1.20
1.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-70.50
-56.00
-25.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -25.89% vs -80.06% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-285.40
-172.80
-65.16%
Interest
4.70
3.10
51.61%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-252.10
-151.80
-66.07%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -66.07% vs -35.54% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Akero Therapeutics, Inc. stock-summary
stock-summary
Akero Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).
Company Coordinates stock-summary
Company Details
601 Gateway Boulevard, Suite 350 , SOUTH SAN FRANCISCO CA : 94080
stock-summary
Tel: 1 650 4876488
stock-summary
https://www.akerotx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."